Conduit Pharmaceuticals Inc. (NASDAQ:CDT – Get Free Report) major shareholder Ltd Nirland sold 333,177 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $0.10, for a total transaction of $33,317.70. Following the completion of the transaction, the insider now directly owns 9,900,000 shares of the company’s stock, valued at approximately $990,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Ltd Nirland also recently made the following trade(s):
- On Monday, September 30th, Ltd Nirland sold 1,016,823 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.12, for a total transaction of $122,018.76.
Conduit Pharmaceuticals Trading Down 10.4 %
Shares of Conduit Pharmaceuticals stock traded down $0.01 during trading on Wednesday, hitting $0.10. The stock had a trading volume of 4,309,752 shares, compared to its average volume of 4,470,719. Conduit Pharmaceuticals Inc. has a fifty-two week low of $0.10 and a fifty-two week high of $8.75. The business has a fifty day moving average of $0.16 and a two-hundred day moving average of $1.60.
Wall Street Analyst Weigh In
Separately, Berenberg Bank upgraded Conduit Pharmaceuticals to a “strong-buy” rating in a research note on Friday, July 26th.
Read Our Latest Stock Report on CDT
About Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
See Also
- Five stocks we like better than Conduit Pharmaceuticals
- Dividend Capture Strategy: What You Need to Know
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
